Facial Pain Clinical Trial
Official title:
Evaluation of Vanilloid Receptor Inactivation for Preemptive Analgesia
This study will test the effectiveness of the drug capsaicin in controlling pain after third
molar (wisdom tooth) extraction. Capsaicin, the ingredient in chili peppers that makes them
"hot," belongs to a class of drugs called vanilloids, which have been found to temporarily
inactivate pain-sensing nerves.
Healthy normal volunteers between 16 and 40 years of age who require third molar (wisdom
tooth) extraction may be eligible for this study. Participants will undergo the following
procedures in three visits:
Visit 1:
Patients will have touch (sensory) testing by the following three methods: 1) a warm sensor
applied to the gums and the patient will rate when they first feel heat and when the heat
feels painful; 2) the bristles of a small paint brush will be gently stroked across the
gums, and the patient will say whether it feels painful; 3) a light touch will be applied to
the gums with a small needle, and the patient will rate the pain intensity following the
touch.
After testing, patients will be numbed with a local anesthetic (bupivacaine) and then
capsaicin or placebo (an inactive solution) will be injected next to the tooth. The tooth
then will be extracted one day later.
Visit 2:
Patients will return to the clinic after 24 hours to repeat the same type of sensory
testing. After testing, patients will be sedated and numbed with a local anesthetic
(lidocaine) and given an intravenous injection of either saline or ketorolac (30 mg). After
the extraction, pain ratings will be recorded every 20 minutes, for up to 6 hours. During
this time, patients will be monitored for numbness, pain, side effects and vital signs
(heart rate, blood pressure, respiration, etc.). Those who request pain medicine will
receive acetaminophen and codeine. Patients will be required to stay for up to 3 more hours
after this and then they will then be discharged with pain medicine.
Visit 3:
Patients will return to the clinic after another 48 hours to repeat the same sensory
testing. Remaining wisdom teeth will be removed "off-study" at least three weeks following
the first visit.
Successful preemptive analgesia strategies are superior to traditional pain management schemes in the management of post-operative pain. However, agents with appropriate pharmacokinetic properties are not readily available. The premise of this double-blind, placebo and positive-controlled clinical study is to evaluate the efficacy of vanilloid agonists as preemptive agents in an oral surgery tissue injury model. Vanilloids are a class of small organic compounds; the most familiar of which is capsaicin, the active ingredient in hot pepper. Binding of capsaicin to the vanilloid-1 receptor produces initial activation and then long-acting desensitization of pain specific neurons. We propose to produce a selective, long-term inactivation of peripheral pain transmission through the local application of capsaicin in the oral mucosa in an effort to prevent or reduce post-operative pain in the oral surgery model. Healthy subjects will be recruited, and following local anesthesia, will be given an intramucosal injection of either capsaicin or placebo. (Or as a positive control, 24 hours later, intravenous Toradol). Subjects will have one lower impacted wisdom tooth extracted under local anesthesia and then will rate their pain. The time of analgesic rescue medication request will be noted. A decrease in post-operative pain and decrease in analgesic use will be taken as a positive effect of the vanilloid for decreasing post-operative pain. We anticipate that through the long term blockade of pain specific fibers pre-operatively that there will be a significant attenuation of post-operative pain development following surgery. This has significant implications for reducing pain and suffering, decreasing analgesic use, and reducing post-operative complications following surgery. ;
Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02957097 -
Gabapentin as a Pre-emptive Analgesic in Oral and Maxillofacial Surgical Procedures
|
Phase 4 | |
Recruiting |
NCT05615714 -
Paresthesia-free Peripheral Nerve Field Stimulation for Trigeminal Neuralgia (FreeST Trial)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01554332 -
Motor Cortex Stimulation for Chronic Neuropathic Pain
|
N/A | |
Terminated |
NCT01849796 -
Transcranial Stimulation (tDCS) For the Treatment of Neuropathic Facial Pain
|
Phase 2 | |
Completed |
NCT00462566 -
The Efficacy of Motor Cortex Stimulation for Pain Control
|
N/A | |
Active, not recruiting |
NCT05147454 -
MRI & QST Analysis in Trigeminal Neuralgia and Persistent Idiopathic Facial Pain
|
||
Completed |
NCT04819763 -
Physical Exercises for Temporomandibular Disorders
|
N/A | |
Completed |
NCT03462290 -
Botox Injections for Patients With Persistent Facial Pain
|
Phase 2 | |
Active, not recruiting |
NCT04779476 -
Effectiveness of Alveogyl and Cutanplast Dressing on Postoperative Pain Following Tooth Extraction: A Clinical Trial
|
||
Recruiting |
NCT05479604 -
Treatment of Sinus Headache Using a Novel Device That Combines Acoustic Vibration With Oscillating Expiratory Pressure
|
N/A | |
Active, not recruiting |
NCT02131714 -
Pressure Pain Threshold of Jaw Muscles in TMD Patients Submitted to a Conservative Treatment
|
N/A | |
Completed |
NCT05240703 -
Stabilization Splint Treatment of TMD
|
N/A | |
Terminated |
NCT00122915 -
CONCEPT: Crossover Efficacy Pain Trial in Motor Cortex Stimulation for Intractable Neuropathic Pain
|
Phase 3 | |
Completed |
NCT00355160 -
Non-Rhinologic Etiologies of Headaches and Facial Pain in Tertiary Care Setting
|
N/A | |
Recruiting |
NCT04467398 -
Incidence of Intravascular (IV) Injection During Trigeminal Nerve Blocks
|
||
Completed |
NCT02021357 -
Proprioceptive Treatment for Temporomandibular Dysfunction
|
N/A | |
Completed |
NCT03189823 -
Long-term Effect of Motor Cortex Stimulation in Patients Suffering From Chronic Neuropathic Pain
|
N/A | |
Enrolling by invitation |
NCT06299995 -
Phenotype and Burden of a Midfacial Segment Pain
|
||
Completed |
NCT04249427 -
Erenumab for Idiosyncratic Facial Pain
|
Phase 4 | |
Completed |
NCT02729480 -
Clinical Trial of Wireless CranioFacial Nerve Stimulation (CFNS) for the Treatment of CranioFacial Neuropathic Pain
|
N/A |